WA-SCHULTZ-FAMILY-FND
13.2.2024 21:54:28 CET | Business Wire | Press release
Trilogy Films, the renowned production company led by award-winning Director Dawn Porter, is thrilled to announce an unprecedented collaboration with the Schultz Family Foundation to produce a feature-length documentary about one of the most iconic, politically-charged partnerships in history: the remarkable, largely untold story of Nelson and Winnie Mandela.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240212248716/en/
Nelson and Winnie Mandela after his liberation from prison in South Africa on February 11, 1990. Photo by Pool BOUVET/DE KEERLE/Gamma-Rapho via Getty Images.
Based on the book by noted South African writer and scholar Jonny Steinberg, Winnie and Nelson: Portrait of a Marriage, the film will explore the Mandelas’ profound bond and how their marriage was inextricably entangled with the struggle against apartheid. The film promises an intimate portrayal of Nelson and Winnie’s marriage, delving into their vehement and volatile connection from their early years to their mutual goal of dismantling apartheid. Their journey culminates in Nelson Mandela’s historic election as South Africa’s first democratically elected President. This cinematic exploration captures the essence of their indomitable spirits and the global impact of their love and advocacy.
Dawn Porter, celebrated for her exceptional storytelling that explores the overlooked, reveals the consequences of policy and social action, champions the marginalized, and offers a fresh perspective on the familiar, is at the helm of the production. With her profound ability to craft narratives that deeply resonate with and inform audiences, Porter is poised to bring a unique lens to the enduring love story of Nelson and Winnie Mandela.
“Creating a film about Nelson Mandela’s life is an extraordinary privilege, and I am genuinely thrilled about the collaboration with the Schultz Family Foundation and Trilogy Films,” said Dawn Porter. “Nelson Mandela’s journey exemplifies the resilience and capacity for change within the human spirit. We aspire to share this incredible odyssey with audiences around the globe. But his story is incomplete without exploring the relationship with his most influential and intimate advisor – his wife Winnie. There can be no definitive Mandela story without understanding the complicated dynamics of their relationship.”
The collaboration with Trilogy Films marks the Schultz Family Foundation’s first venture into transformative storytelling projects – across scripted and documentary films and series, podcasts, and books – linked to its mission of creating greater opportunity, accessible to all. The Schultz Family Foundation’s involvement transcends financial support; it embodies a philanthropic vision and commitment to tell truthful, aspirational stories that have the power to reveal hidden narratives, spark hope, spotlight solutions, and restore confidence during a time of enormous pessimism, dissension, misinformation, and a fracturing of trust in traditional institutions, leadership, and each other.
“At its heart, Winnie and Nelson is a complicated story of leadership, conflict, love, and extraordinary sacrifice in the face of unfathomable brutality where the future of a democracy was at stake,” said Howard Schultz, co-founder of the Schultz Family Foundation and chairman emeritus of Starbucks Corporation. “My wife Sheri and I feel privileged and humbled by the opportunity to partner with such a respected and talented director as Dawn to bring this film to life. We believe in the power of human-centered, aspirational storytelling to nurture our common bonds, foster our shared humanity, and inspire the next generation of leaders, and we look forward to pursuing other projects across many different formats aligned with our family’s philanthropic work and mission.”
About Trilogy Films:
Trilogy Films, founded by award-winning director Dawn Porter, directs and produces non-fiction content that tells untold stories, shares new perspectives, and reveals the complex humanity of some of history’s most iconic figures. Porter's acclaimed films include "Gideon’s Army" (2013), "Spies of Mississippi” (2014), and “Bobby Kennedy for President” (2018). Her latest work, “Luther: Never Too Much,” debuted to rave reviews at the 2024 Sundance Film Festival and was lauded as the best of fest in multiple news outlets. 2023 was a banner year for Porter and Trilogy. The Critics Choice nominated “Lady Bird Diaries," an all archival documentary showcasing Lady Bird Johnson, premiered at the 2023 SXSW Film Festival, while her four-part docuseries "Deadlocked: How America Shaped the Supreme Court” also garnered nominations for a Critics Choice Documentary Award as well as a Film Independent Spirit Award.
About the Schultz Family Foundation:
The Schultz Family Foundation’s mission is to create greater opportunity, accessible to all. Our work is deeply rooted in the lives and values of our co-founders, Sheri and Howard Schultz, who believe talent is everywhere, but opportunity is not. We seek to apply the lessons they have learned over the decades to seed innovations and scale solutions to help young people successfully navigate the transition to adulthood and positively impact the trajectory of their lives. We are investors in unleashing potential and unlocking opportunity, working in partnership with employers, entrepreneurs, non-profits, and governments that share our aspiration of enabling everyone to access the full promise of America. For more information about the Foundation and its work: www.schultzfamilyfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240212248716/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
